AMEND is delighted to be able to fund 4 important research efforts for 2015. Thanks to the exceptional fundraising efforts during 2014 by the family, friends and colleagues of the late Chris Murray, we have a special fund for medullary thyroid cancer (MTC) this year worth £40,000. MTC is responsible for the majority of deaths in MEN2a and MEN2b. The MTC Fund is in addition to our annual general award of £10,000. Click on the projects below to learn more about them and the people behind them. AMEND Research Award Winners often attend our Annual Patient Information Days to present their research and answer questions, so do come along in 2016!
MEN (Total Fund £10,000)
- Dr Paul Newey (Dundee): Developing stem cell based models of MEN1-associated pancreatic neuroendocrine tumours (PanNETs) - a tool for drug discovery (£9,990)
MTC (Special 2015 Fund £40,000)
- Professor Neil McDonald (Francis Crick Institute, London): Profiling drug-resistant MEN2/MTC RET variants for novel chemical inhibitor sensitivities (£15,000)
- Professor Chris McCabe (Birmingham): Genome editing to determine the role of oestrogen receptor beta in MTC (£15,912)
- Dr Laura Moss (Cardiff): QaLM - Assessing Quality of Life in MTC Patients (£9,030)